Pacmilimab by CytomX Therapeutics for Adenocarcinoma: Likelihood of Approval

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Adenocarcinoma.

Source link
#Pacmilimab #CytomX #Therapeutics #Adenocarcinoma #Likelihood #Approval